Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
JD HEALTH
06618
5
ALI HEALTH
00241
| (FY)Jun 30, 2025 | (FY)Jun 30, 2024 | (FY)Jun 30, 2023 | (FY)Jun 30, 2022 | (FY)Jun 30, 2021 | (FY)Jun 30, 2020 | (FY)Jun 30, 2019 | (FY)Jun 30, 2018 | |
|---|---|---|---|---|---|---|---|---|
| Total revenue | 254.91%11.83M | 190.03%3.33M | -45.33%1.15M | 1,633.05%2.1M | -54.60%121.3K | -74.32%267.2K | 1.04M | |
| Operating revenue | 254.91%11.83M | 190.03%3.33M | -45.33%1.15M | 1,633.05%2.1M | -54.60%121.3K | -74.32%267.2K | --1.04M | ---- |
| Cost of revenue | 290.35%10.32M | 208.71%2.64M | -56.55%856.42K | 3,321.27%1.97M | -76.04%57.61K | -78.03%240.38K | 1.09M | |
| Gross profit | 119.03%1.51M | 135.40%689.45K | 122.95%292.89K | 106.25%131.37K | 137.47%63.7K | 149.97%26.82K | -53.68K | |
| Operating expense | 43.52%1.73M | 13.47%1.21M | -33.36%1.06M | 49.52%1.6M | -42.59%1.07M | -7.11%1.86M | -18.82%2M | 2.47M |
| Selling and administrative expenses | 43.12%1.72M | 12.68%1.2M | -33.36%1.06M | 57.29%1.6M | -43.66%1.01M | -10.03%1.8M | 54.11%2M | --1.3M |
| -General and administrative expense | 43.12%1.72M | 12.68%1.2M | -33.36%1.06M | 57.29%1.6M | -43.66%1.01M | -10.03%1.8M | 54.11%2M | --1.3M |
| Research and development costs | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1.17M |
| Depreciation amortization depletion | 100.00%16.63K | --8.32K | ---- | ---- | -9.78%52.74K | --58.46K | ---- | ---- |
| -Depreciation and amortization | 100.00%16.63K | --8.32K | ---- | ---- | -9.78%52.74K | --58.46K | ---- | ---- |
| Operating profit | 57.13%-221.77K | 32.87%-517.32K | 47.38%-770.67K | -45.92%-1.46M | 45.23%-1M | 10.84%-1.83M | 16.65%-2.06M | -2.47M |
| Net non-operating interest income (expenses) | -72.26%-9.77K | -711.65%-5.67K | 572.96%927 | 35.53%-196 | 91.10%-304 | -144.91%-3.42K | -81.01%7.6K | 40.04K |
| Non-operating interest income | -62.40%614 | -54.75%1.63K | 987.05%3.61K | -71.38%332 | -67.27%1.16K | -65.85%3.54K | -75.59%10.38K | --42.51K |
| Non-operating interest expense | 42.15%10.38K | 172.30%7.3K | 407.95%2.68K | -63.93%528 | -78.96%1.46K | 150.96%6.96K | 12.36%2.77K | --2.47K |
| Other net income (expenses) | -37.08%138.77K | -7.96%220.56K | 30.51%239.62K | -51.19%183.6K | -29.32%376.13K | 11.96%532.15K | 389.18%475.31K | 97.17K |
| Other non-operating income (expenses) | -37.08%138.77K | -7.96%220.56K | 30.51%239.62K | -51.19%183.6K | -29.32%376.13K | 11.96%532.15K | 389.18%475.31K | --97.17K |
| Income before tax | 74.12%-76.13K | 44.52%-294.12K | 58.63%-530.12K | -104.04%-1.28M | 51.84%-627.94K | 17.08%-1.3M | 32.47%-1.57M | -2.33M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Earnings from equity interest net of tax | ||||||||
| Net income | 74.12%-76.13K | 44.52%-294.12K | 58.63%-530.12K | -104.04%-1.28M | 51.84%-627.94K | 17.08%-1.3M | 32.47%-1.57M | -2.33M |
| Net income continuous operations | 74.12%-76.13K | 44.52%-294.12K | 58.63%-530.12K | -104.04%-1.28M | 51.84%-627.94K | 17.08%-1.3M | 32.47%-1.57M | ---2.33M |
| Noncontrolling interests | ||||||||
| Net income attributable to the company | 74.12%-76.13K | 44.52%-294.12K | 58.63%-530.12K | -104.04%-1.28M | 51.84%-627.94K | 17.08%-1.3M | 32.47%-1.57M | -2.33M |
| Preferred stock dividends | ||||||||
| Other under preferred stock dividend | ||||||||
| Net income attributable to common stockholders | 74.12%-76.13K | 44.52%-294.12K | 58.63%-530.12K | -104.04%-1.28M | 51.84%-627.94K | 17.08%-1.3M | 32.47%-1.57M | -2.33M |
| Diluted earnings per share | 75.86%-0.0007 | 44.23%-0.0029 | 59.38%-0.0052 | -64.10%-0.0128 | 53.22%-0.0078 | 16.75%-0.0167 | 45.29%-0.02 | -0.0366 |
| Basic earnings per share | 75.86%-0.0007 | 44.23%-0.0029 | 59.38%-0.0052 | -64.10%-0.0128 | 53.22%-0.0078 | 16.75%-0.0167 | 45.29%-0.02 | -0.0366 |
| Dividend per share | ||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |